Research programme: HIV capsid assembly inhibitors - Achillion/University of Maryland
Latest Information Update: 05 Feb 2020
At a glance
- Originator Achillion Pharmaceuticals; University of Maryland, Baltimore
- Class Small molecules
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 01 May 2007 This programme is still in development
- 07 Apr 2003 Preclinical trials in HIV infections treatment in USA (unspecified route)